Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29250309 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2BCHECHRM2CHRM1 | |
| SCHEMBL5773612 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2BCHECHRM2CHRM1 | |
| SCHEMBL27771573 | 0.75 | BCHE (0.39) | USP2SMN1; SMN2BCHECHRM2CHRM1 | |
| SCHEMBL5858067 | 0.75 | USP2 (0.40) | USP2SMN1; SMN2BCHECHRM2CHRM1 | |
| SCHEMBL29029079 | 0.75 | USP2 (0.36) | USP2SMN1; SMN2BCHECHRM2CHRM1 | |
| SCHEMBL29056833 | 0.75 | USP2 (0.33) | USP2SMN1; SMN2BCHECHRM2CHRM1 | |
| SCHEMBL30805636 | 0.74 | USP2 (0.38) | USP2SMN1; SMN2BCHECHRM2CHRM1 | |
| SCHEMBL3355846 | 0.72 | USP2 (0.33) | USP2SMN1; SMN2BCHEGPR119 | |
| SCHEMBL28898488 | 0.72 | USP2 (0.39) | USP2SMN1; SMN2BCHECHRM2CHRM1 | |
| SCHEMBL28026573 | 0.69 | BCHE (0.35) | USP2SMN1; SMN2BCHECHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1681811-B | Azolidinone-vinyl fused-benzene derivatives | APPLIED RESEARCH SYSTEMS | 2010-05-26 | — | — | CN | claimed |
| CN-1681811-A | Azolidinone-vinyl fused-benzene derivatives | APPLIED RESEARCH SYSTEMS (AN) | 2005-10-12 | — | — | CN | claimed |
| CN-116283916-B | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2024-06-11 | — | — | CN | disclosed |
| CN-118103369-A | Pyridolactam derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117917406-A | Heterocyclic compounds, process for their preparation and their use | 四川科伦博泰生物医药股份有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-113226310-B | 15-PGDH inhibitors | 杏林制药株式会社 | 2024-03-19 | — | — | CN | disclosed |
| CN-117355522-A | PKC-theta modulators | 爱智药人工智能有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-112204028-B | tetrahydro-1H-pyrazino [2,1-a ] isoindoloquinoline compounds for use in the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117024411-A | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116997548-A | HTT modulators for the treatment of huntington's disease | CHDI基金会股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-1933853-B | Drug conjugates | UNIV NEW YORK STATE RES FOUND | 2010-05-12 | — | — | CN | disclosed |
| CN-101300047-A | PI3K inhibitors for the treatment of endometriosis | SERONO LAB (CH) | 2008-11-05 | — | — | CN | disclosed |
| US-20080139815-A1 | DRUG CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-06-12 | — | — | US | disclosed |
| US-7282590-B2 | Selectively target tumor cells with highly potent cytotoxic drugs at a drug release rate that is effective for the destruction and/or inhibition of tumor cells | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-10-16 | — | — | US | disclosed |
| CN-1933853-A | Drug conjugates | UNIV NEW YORK (US) | 2007-03-21 | — | — | CN | disclosed |
| US-20050232928-A1 | Drug conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-20 | — | — | US | disclosed |
| CN-1681811-A | Azolidinone-vinyl fused-benzene derivatives | APPLIED RESEARCH SYSTEMS (AN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1335845-A | 3,4-dihydro-2H-benzo[1,4] oxazinyl-methyl [3-(1H-indol-3-yl)-alkyl]-amines | AMERICAN HOME PROD (US) | 2002-02-13 | — | — | CN | disclosed |
| CN-1304409-A | Indol-3-Yl-cyclohexyl amide derivatives for treatment of depression (5-HT1 receptor antagonists) | AMERICAN HOME PROD (US) | 2001-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232928-A1 | Drug conjugates | RXRB, NR0B1, RXRA | USP2 4075/4885SMN1; SMN2 2619/4885BCHE 560/4885 |
| US-20080139815-A1 | DRUG CONJUGATES | RXRB, NR0B1, RXRA | USP2 4015/4885SMN1; SMN2 2627/4885BCHE 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.